UniProt ID | NOC3L_HUMAN | |
---|---|---|
UniProt AC | Q8WTT2 | |
Protein Name | Nucleolar complex protein 3 homolog | |
Gene Name | NOC3L | |
Organism | Homo sapiens (Human). | |
Sequence Length | 800 | |
Subcellular Localization | Nucleus, nucleolus. Nucleus speckle. | |
Protein Description | May be required for adipogenesis.. | |
Protein Sequence | MKARRNKKQIPSFRKLIKTSKVKLENKLKNKQFKQQSTLKKYRKEQRKLRQAVKDAVSKKPIPLENPKEKRPGKRIEREEEEEEEALPLDMMDEDDLQLMKDLGQRVSFLTRDLSSSEPVHAKKRKHERIIDKYEKIPRTLQTAPEKELIHLLPIKDKSGIIPQTREKPVTDSNKDEEDQEEERELEEEIIEDPIQELTIEEHLIERKKKLQEKKMHIAALASAILSDPENNIKKLKELRSMLMEQDPDVAVTVRKLVIVSLMELFKDITPSYKIRPLTEAEKSTKTRKETQKLREFEEGLVSQYKFYLENLEQMVKDWKQRKLKKSNVVSLKAYKGLAEVAVKSLCELLVALPHFNFHNNIIVLIVPLMNDMSKLISEMCCEAVKKLFKQDKLGQASLGVIKVISGFVKGRNYEVRPEMLKTFLCLRIKEVEVKKDTEDINKPKKFMTFKEKRKSLSRMQRKWKKAEEKLERELREAEASESTEKKLKLHTETLNIVFVTYFRILKKAQRSPLLPAVLEGLAKFAHLINVEFFDDLLVVLHTLIESGDLSYQESLHCVQTAFHILSGQGDVLNIDPLKFYTHLYKTLFKLHAGATNEGVEIVLQCLDVMLTKRRKQVSQQRALAFIKRLCTLALHVLPNSSIGILATTRILMHTFPKTDLLLDSESQGSGVFLPELDEPEYCNAQNTALWELHALRRHYHPIVQRFAAHLIAGAPSEGSGALKPELSRRSATELFEAYSMAEMTFNPPVESSNPKIKGKFLQGDSFLNEDLNQLIKRYSSEVATESPLDFTKYLKTSLH | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
23 | Acetylation | LIKTSKVKLENKLKN HHHHCHHHHHHHHCC | 54.54 | 133323 | |
34 | Acetylation | KLKNKQFKQQSTLKK HHCCCHHHHHHHHHH | 44.96 | 133325 | |
37 | Phosphorylation | NKQFKQQSTLKKYRK CCHHHHHHHHHHHHH | 32.96 | 30108239 | |
38 | Phosphorylation | KQFKQQSTLKKYRKE CHHHHHHHHHHHHHH | 37.95 | 30108239 | |
40 | Acetylation | FKQQSTLKKYRKEQR HHHHHHHHHHHHHHH | 48.09 | 133321 | |
59 | Ubiquitination | AVKDAVSKKPIPLEN HHHHHHHCCCCCCCC | 56.84 | 21890473 | |
78 | Ubiquitination | RPGKRIEREEEEEEE CCCCCCCCCHHHHHH | 55.01 | 24816145 | |
108 | Phosphorylation | KDLGQRVSFLTRDLS HHHHHHHHHHHCCCC | 19.41 | 25159151 | |
115 | Phosphorylation | SFLTRDLSSSEPVHA HHHHCCCCCCCCCCC | 35.79 | 25159151 | |
116 | Phosphorylation | FLTRDLSSSEPVHAK HHHCCCCCCCCCCCC | 46.12 | 25159151 | |
117 | Phosphorylation | LTRDLSSSEPVHAKK HHCCCCCCCCCCCCH | 42.41 | 25159151 | |
123 | Acetylation | SSEPVHAKKRKHERI CCCCCCCCHHHHHHH | 37.93 | 25953088 | |
123 | 2-Hydroxyisobutyrylation | SSEPVHAKKRKHERI CCCCCCCCHHHHHHH | 37.93 | - | |
124 | Acetylation | SEPVHAKKRKHERII CCCCCCCHHHHHHHH | 68.42 | 25953088 | |
133 | Acetylation | KHERIIDKYEKIPRT HHHHHHHHHHHCCCC | 44.92 | 26051181 | |
134 | Phosphorylation | HERIIDKYEKIPRTL HHHHHHHHHHCCCCC | 20.78 | - | |
147 | Acetylation | TLQTAPEKELIHLLP CCCCCCHHHHEEEEE | 57.68 | 25953088 | |
159 | Phosphorylation | LLPIKDKSGIIPQTR EEECCCCCCCCCCCC | 45.41 | - | |
171 | Phosphorylation | QTREKPVTDSNKDEE CCCCCCCCCCCCCHH | 42.09 | 19691289 | |
173 | Phosphorylation | REKPVTDSNKDEEDQ CCCCCCCCCCCHHHH | 36.09 | 19691289 | |
195 | Ubiquitination | EEIIEDPIQELTIEE HHHHHCHHHHCCHHH | 8.43 | 27667366 | |
223 | Phosphorylation | MHIAALASAILSDPE HHHHHHHHHHHCCCC | 19.38 | 20068231 | |
227 | Phosphorylation | ALASAILSDPENNIK HHHHHHHCCCCCHHH | 45.03 | 20068231 | |
241 | Phosphorylation | KKLKELRSMLMEQDP HHHHHHHHHHHHCCC | 28.97 | 20068231 | |
253 | Phosphorylation | QDPDVAVTVRKLVIV CCCCHHHHHHHHHHH | 12.59 | 20068231 | |
261 | Phosphorylation | VRKLVIVSLMELFKD HHHHHHHHHHHHHCC | 15.75 | 24670416 | |
273 | Phosphorylation | FKDITPSYKIRPLTE HCCCCCCCCCCCCCH | 16.19 | - | |
274 | Ubiquitination | KDITPSYKIRPLTEA CCCCCCCCCCCCCHH | 36.25 | 22817900 | |
284 | Phosphorylation | PLTEAEKSTKTRKET CCCHHHHHCCCHHHH | 27.00 | 26074081 | |
285 | Phosphorylation | LTEAEKSTKTRKETQ CCHHHHHCCCHHHHH | 47.72 | 26074081 | |
287 | Phosphorylation | EAEKSTKTRKETQKL HHHHHCCCHHHHHHH | 47.24 | 26074081 | |
293 | Ubiquitination | KTRKETQKLREFEEG CCHHHHHHHHHHHHH | 57.86 | 24816145 | |
333 | Acetylation | KSNVVSLKAYKGLAE CCCCCCHHHHCCHHH | 42.01 | 25953088 | |
333 | Sumoylation | KSNVVSLKAYKGLAE CCCCCCHHHHCCHHH | 42.01 | 28112733 | |
386 | Acetylation | EMCCEAVKKLFKQDK HHHHHHHHHHHHCCC | 51.29 | 25953088 | |
390 | Acetylation | EAVKKLFKQDKLGQA HHHHHHHHCCCCCCH | 68.94 | 26051181 | |
398 | Phosphorylation | QDKLGQASLGVIKVI CCCCCCHHHHHHHHH | 20.12 | 20068231 | |
410 | Ubiquitination | KVISGFVKGRNYEVR HHHHCCCCCCCCCCC | 50.30 | 27667366 | |
410 | Acetylation | KVISGFVKGRNYEVR HHHHCCCCCCCCCCC | 50.30 | 26051181 | |
422 | Acetylation | EVRPEMLKTFLCLRI CCCHHHHHHHHHHHC | 35.60 | 26051181 | |
430 | Acetylation | TFLCLRIKEVEVKKD HHHHHHCCEEEECCC | 49.64 | 26051181 | |
443 | Acetylation | KDTEDINKPKKFMTF CCCCCCCCCCCCCCH | 59.56 | 26051181 | |
445 | 2-Hydroxyisobutyrylation | TEDINKPKKFMTFKE CCCCCCCCCCCCHHH | 61.32 | - | |
449 | Phosphorylation | NKPKKFMTFKEKRKS CCCCCCCCHHHHHHH | 34.39 | 28555341 | |
456 | Phosphorylation | TFKEKRKSLSRMQRK CHHHHHHHHHHHHHH | 35.29 | 24719451 | |
481 | Phosphorylation | ELREAEASESTEKKL HHHHHHHCHHHHHHH | 24.48 | 20068231 | |
483 | Phosphorylation | REAEASESTEKKLKL HHHHHCHHHHHHHHH | 39.09 | 20068231 | |
484 | Phosphorylation | EAEASESTEKKLKLH HHHHCHHHHHHHHHH | 48.01 | 20068231 | |
492 | Phosphorylation | EKKLKLHTETLNIVF HHHHHHHHHHHHHHH | 40.89 | - | |
494 | Phosphorylation | KLKLHTETLNIVFVT HHHHHHHHHHHHHHH | 26.68 | - | |
567 | Phosphorylation | QTAFHILSGQGDVLN HHHHHHHCCCCCCCC | 28.59 | 24719451 | |
628 | Sumoylation | QRALAFIKRLCTLAL HHHHHHHHHHHHHHH | 32.63 | - | |
628 | 2-Hydroxyisobutyrylation | QRALAFIKRLCTLAL HHHHHHHHHHHHHHH | 32.63 | - | |
628 | Sumoylation | QRALAFIKRLCTLAL HHHHHHHHHHHHHHH | 32.63 | - | |
717 | Phosphorylation | HLIAGAPSEGSGALK HHHHCCCCCCCCCCC | 54.80 | 20068231 | |
720 | Phosphorylation | AGAPSEGSGALKPEL HCCCCCCCCCCCHHH | 19.48 | 20068231 | |
724 | Acetylation | SEGSGALKPELSRRS CCCCCCCCHHHHHHC | 35.59 | 26051181 | |
728 | Phosphorylation | GALKPELSRRSATEL CCCCHHHHHHCHHHH | 24.80 | 20068231 | |
760 | Acetylation | SNPKIKGKFLQGDSF CCCCCCCCCCCCCCC | 37.59 | 25953088 | |
760 | Ubiquitination | SNPKIKGKFLQGDSF CCCCCCCCCCCCCCC | 37.59 | 29967540 | |
777 | Ubiquitination | EDLNQLIKRYSSEVA HHHHHHHHHHCHHCC | 54.60 | 29967540 | |
779 | Phosphorylation | LNQLIKRYSSEVATE HHHHHHHHCHHCCCC | 16.14 | 23663014 | |
780 | Phosphorylation | NQLIKRYSSEVATES HHHHHHHCHHCCCCC | 24.85 | 23663014 | |
781 | Phosphorylation | QLIKRYSSEVATESP HHHHHHCHHCCCCCC | 27.44 | 23663014 | |
785 | Phosphorylation | RYSSEVATESPLDFT HHCHHCCCCCCCHHH | 42.02 | 30266825 | |
787 | Phosphorylation | SSEVATESPLDFTKY CHHCCCCCCCHHHHH | 26.80 | 23927012 | |
792 | Phosphorylation | TESPLDFTKYLKTSL CCCCCHHHHHHHHCC | 20.60 | 23663014 | |
793 | Ubiquitination | ESPLDFTKYLKTSLH CCCCHHHHHHHHCCC | 48.88 | 29967540 | |
793 | Acetylation | ESPLDFTKYLKTSLH CCCCHHHHHHHHCCC | 48.88 | 26051181 | |
794 | Phosphorylation | SPLDFTKYLKTSLH- CCCHHHHHHHHCCC- | 15.46 | 23663014 | |
796 | Ubiquitination | LDFTKYLKTSLH--- CHHHHHHHHCCC--- | 32.74 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of NOC3L_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of NOC3L_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of NOC3L_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
DDX24_HUMAN | DDX24 | physical | 26344197 | |
PESC_HUMAN | PES1 | physical | 26344197 | |
RL4_HUMAN | RPL4 | physical | 26344197 | |
RLA0_HUMAN | RPLP0 | physical | 26344197 | |
RRP12_HUMAN | RRP12 | physical | 26344197 | |
SRP72_HUMAN | SRP72 | physical | 26344197 | |
TBL3_HUMAN | TBL3 | physical | 26344197 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-787, AND MASSSPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-787, AND MASSSPECTROMETRY. | |
"Evaluation of the low-specificity protease elastase for large-scalephosphoproteome analysis."; Wang B., Malik R., Nigg E.A., Korner R.; Anal. Chem. 80:9526-9533(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115 AND SER-117, ANDMASS SPECTROMETRY. | |
"Phosphoproteome analysis of the human mitotic spindle."; Nousiainen M., Sillje H.H.W., Sauer G., Nigg E.A., Koerner R.; Proc. Natl. Acad. Sci. U.S.A. 103:5391-5396(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-787, AND MASSSPECTROMETRY. |